Group 1: Industry Trends and Market Dynamics - The pharmaceutical equipment industry is experiencing a slowdown in growth due to the end of GMP certification, with a market contraction expected as a result of policy changes and the transition to a new normal in China's economy [3][4] - Despite the apparent downturn, the pharmaceutical industry maintained a 20% growth rate over the past year, indicating that the absolute market size has not decreased [4] - The Chinese pharmaceutical equipment production remains the largest globally, but the overall technology quality is still at a mid to lower level, suggesting room for improvement and innovation [4] Group 2: Company Strategy and Product Development - The company anticipates that traditional linked line product sales have reached their lowest point, with a return to normalcy expected in approximately three years [5] - Intelligent manufacturing is identified as a key development direction, with specific applications in self-detection and self-correction capabilities for machines [5][6] - The company is focusing on upgrading traditional linked line products, with initial implementations in areas such as ampoule bottles and oral solutions [6] Group 3: Financial Projections and Sales Goals - For 2015, the company aims to maintain traditional linked line product sales while achieving new product sales targets: approximately 70-80 million for liquid preparation systems, 50 million for intelligent post-packaging, and 150 million for intelligent inspection machines [9] - The company plans to achieve a sales target of 20 billion through both organic growth and acquisitions, supported by a significant increase in technical personnel across its research institutes [10] Group 4: Workforce and Talent Management - The company has streamlined its management structure, reducing the number of management personnel while increasing sales and R&D staff, with plans to recruit 50-100 R&D talents annually from top universities [8]

Group 1: Company Growth and Product Development - The company has maintained good growth in recent years and is cautiously optimistic about future growth due to inherent unpredictability in business [3] - New product prototypes planned for this year have passed testing, with potential delays primarily due to internal factors rather than external ones [3] - The freeze-drying series achieved over 300 million in revenue last year, with a projected growth rate of 50% this year [4] Group 2: Market Potential and Strategic Planning - The market for intelligent post-packaging and fluid dispensing systems is large, with potential for significant growth upon market introduction [4] - The company's five-year plan aims for sales revenue of 6 billion, with an expected composition of 80% products and 20% overall solutions [4] - The growth in the freeze-drying sector is driven by increasing market capacity and the exit of less competitive firms [4] Group 3: Production Capacity and Financial Performance - The company’s fundraising project is expected to be completed by June, with an overall capacity target of 2 billion [5] - The gross margin for the freeze-drying series is expected to recover this year, influenced by market competition and quality improvements [6] - The company plans to enhance its production efficiency through technology upgrades in the pharmaceutical equipment sector [7] Group 4: International Sales and Future Directions - Current overseas sales are primarily focused on regions such as the former Soviet Union, India, Southeast Asia, and South America [7] - The company’s future direction will remain centered on the pharmaceutical equipment industry, with potential cross-industry applications [7] - The company plans to introduce stock incentive programs for mid-to-senior management and key technical and sales personnel [7] Group 5: Mergers and Acquisitions Strategy - The company’s M&A strategy will focus on the pharmaceutical equipment sector or related industries, emphasizing brand reputation and technological leadership [8] - The company is exploring two directions in robotics research: pharmaceutical robots for process automation and rehabilitation robots for assisting the elderly and disabled [9]

Financial Performance - Revenue for the first three quarters of 2021 reached 3.682 billion, a 67% increase from 2.202 billion in the same period of 2020 [3] - Net profit for the same period was 406 million, up 728% from 49 million in 2020 [3] - Operating cash flow net amount was 1.265 billion, a 379% increase from 264 million in 2020 [3] - Contract liabilities as of September 2021 were 2.534 billion, a 32% increase from 1.924 billion at the end of the previous half [3] - Orders on hand were approximately 6.2 billion as of September 2021 [3] - R&D expenses amounted to 308 million, a 61% increase from 191 million in 2020 [3] Market Strategy - The company aims to maintain its leading position in sterile packaging and testing post-packaging products [4] - Focus on developing biopharmaceutical equipment, especially front-end equipment and consumables [4] - Plans to establish a dedicated team for innovative drug equipment development [4] - Targeting a domestic market share of 10-15%, equivalent to 10-15 billion, currently imported from abroad [4] - Strong emphasis on expanding overseas business and establishing localized sales service companies [4] Future Goals - The company believes achieving its 2030 revenue target depends on the robust growth of the global biopharmaceutical sector [4] - The integration of advanced technologies like Industry 4.0, 5G, and future 6G will blur business boundaries and enhance competitiveness [4] - The company is prioritizing product technology and manufacturing technology to improve market competitiveness [4] Import Substitution - The company is increasing its focus on import substitution, which will be a key theme in 2022 [5] - High-end products are priced at 80-90% of leading foreign competitors, maintaining a gross margin above 40% [5] - Normal gross margin levels for domestic companies are around 40-45%, with net margins between 10-15% [5] Product Development - Key growth products include biopharmaceutical process equipment and complex formulations [5] - The establishment of a subsidiary in Shanghai aims to achieve a production capacity of 200 million for single-use bioreactors and related products [5] - Plans for a new facility in Ningxiang with a capacity of 800-1 billion are underway [5] Integration Success - Successful integration measures with ROMACO include cultural fusion, strategic collaboration, and management alignment [6] - Employee benefits were maintained post-acquisition, with an increase in ROMACO's workforce [6] - Local government interests were supported through effective management and increased tax contributions [6]

Group 1: Company Overview and Recent Developments - Chutian Technology has prioritized product technology and manufacturing excellence, achieving industry-leading standards in product appearance and quality [2][3] - The acquisition of ROMACO has positively influenced Chutian's operations, with ROMACO maintaining stable growth despite the pandemic [3] Group 2: Integration and Management Strategies - Successful integration measures include cultural respect, strategic collaboration, and regular management meetings to align operations [3] - Employee benefits have been maintained post-acquisition, with an increase in ROMACO's workforce [3] Group 3: Future Growth and Product Development - Key growth areas include biopharmaceutical-related equipment and complex formulation products [4] - By 2025, international sales are projected to account for 40%-50% of total revenue [4] Group 4: Market Dynamics and Industry Outlook - The pharmaceutical equipment industry is experiencing increased concentration, benefiting leading companies through higher demands for product and manufacturing technology [4] - Post-pandemic, Chutian aims to capture market demand through high-end vaccine product offerings and import substitution strategies [4]

楚天科技股份有限公司 2022 年第三季度报告 □是 否 证券代码：300358 证券简称：楚天科技 公告编号：2022-097 楚天科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 本报告期比上年同期 年初至报告期末 | --- | --- | --- | --- | --- | |------------------------------------------------------|-------------------|------------------|----------------------- ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|-------|-------|------------|---------------------------------------------------------|--------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 110 00 011 | nnual Report 2022 楚天科技股份有限公司 2022年半年度报告 | | | | | | | | | | | | | | | | | | | | | | | | | 300358 | 楚天科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司 ...

楚天科技股份有限公司 2022 年第一季度报告全文 1 证券代码:300358 证券简称:楚天科技 公告编号：2022-027 号 楚天科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | | | | | | 本报告期 | 上年同期 | 本报告期比上年同期增 ...

楚天科技股份有限公司 2021 年第三季度报告 证券代码：300358 证券简称：楚天科技 公告编号：2021-085 楚天科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|------------------|-------------------|----------- ...

楚天科技股份有限公司 2021 年半年度报告全文 楚天科技股份有限公司 2021 年半年度报告 2021072 2021 年 08 月 1 楚天科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人唐岳、主管会计工作负责人肖云红及会计机构负责人(会计主管 人员)蒋元声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异。本公司请投资者认真阅读 本半年度报告全文，并特别注意下列风险因素： 1、新产品开发不达预期的风险 | --- | |------------------------------------------------------------------------| | | | 公司近几年在生 ...

楚天科技股份有限公司 2021 年第一季度报告全文 楚天科技股份有限公司 2021 年第一季度报告 2021053 2021 年 04 月 1 楚天科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人唐岳、主管会计工作负责人肖云红及会计机构负责人(会计主管 人员)李英姿声明：保证季度报告中财务报表的真实、准确、完整。 2 楚天科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------|------------------|--- ...